Evidence map›Paper›PMID 33860810›Full record

ReviewDer Internist2021

[Chronic obstructive pulmonary disease: the right treatment for the right patient].

Horst Olschewski, Roland Buhl, Georg Christian Funk, Arschang Valipour, Claus F Vogelmeier

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Der Internist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Horst OlschewskiKlinische Abteilung für Pulmonologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. horst.olschewski@medunigraz.at.
Roland BuhlSchwerpunkt Pneumologie, III. Medizinische Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
Georg Christian Funk2. Medizinische Abteilung mit Pneumologie mit AmbulanzKarl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie, Klinik Ottakring, Montleartstr. 37, 1160, Wien, Österreich.
Arschang ValipourAbteilung für Innere Medizin und Pneumologie, Karl-Landsteiner-Institut für Lungenforschung und Pneumologische Onkologie, Klinik Floridsdorf, Brünner Str. 68, 1210, Wien, Österreich.
Claus F VogelmeierKlinik für Innere Medizin, Pneumologie, Intensiv- und Schlafmedizin, Universitätsklinikum Gießen und Marburg, Standort Marburg, Baldingerstr. 1, 35033, Marburg, Deutschland.
Institut für Lungenforschung · DEJohannes Gutenberg University Mainz · DEMedical University of Graz · ATUniversitätsklinikum Gießen und Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, large treatment studies have been published in the field of chronic obstructive pulmonary disease (COPD) and were supplemented by several post-hoc analyses in 2020. The new evidence was incorporated into the 2021 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. This article describes the updated fundamentals of and recommendations for the treatment of COPD. Indications for inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA), and/or long-acting beta-mimetics (LABA) will be addressed. The treatment of COPD is contrasted with that of bronchial asthma. The impact of a concomitant asthma component on the treatment strategy for COPD is also discussed. In addition, the article focuses on triple therapy with LAMA, LABA, and ICS, for which the evidence and indications are described. Bronchodilation remains the foundation of COPD therapy. For patients with clustered exacerbations, triple therapy with LAMA + LABA + ICS confers a mortality benefit. Further analysis or studies are needed to clarify whether this effect is more pronounced for specific subgroups.

Indexed as

Adrenergic beta-2 Receptor AgonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesBronchodilator AgentsDrug Therapy, CombinationHumansMuscarinic AntagonistsAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsAdrenergic beta-agonists, long-actingAsthma, bronchialCorticosteroids, inhaledDisease exacerbationMuscarinic antagonists, long-acting

Identifiers

PMID33860810
PMCPMC8217063
OpenAlexW3152888416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.